Oviva is a digital health platform offering personalised dietetic support for individuals managing type 2 diabetes, prediabetes, and obesity across the NHS. Combining evidence-based behavioural change techniques with remote consultations and a smartphone app, Oviva provides flexible, accessible care tailored to each patient's needs. Commissioned by some Integrated Care Boards in England, the service aims to support sustainable weight loss and improved glycaemic control through ongoing self-tracking, goal-setting, and specialist guidance. This article explores how Oviva works, the clinical evidence supporting its use, NHS availability, and how it compares to traditional diabetes and weight management services.

What Is Oviva and How Does It Support Diabetes and Obesity Management?

Oviva is a digital health platform that provides personalised support for individuals managing type 2 diabetes, prediabetes, and obesity. The service combines evidence-based behavioural change techniques with remote dietetic support, delivered through a smartphone application and regular consultations with registered dietitians. Unlike traditional weight management programmes, Oviva integrates ongoing self-tracking, goal-setting, and professional guidance into a single accessible platform.

The platform is designed to address the interconnected challenges of obesity and type 2 diabetes, conditions that affect millions across the UK. Excess weight is a major modifiable risk factor for developing type 2 diabetes, and weight reduction can significantly improve glycaemic control and reduce cardiovascular risk. NICE guidance (NG28, NG246) recommends that lifestyle interventions target at least 5% weight loss for individuals with obesity and type 2 diabetes. Substantial and sustained weight loss—often 15 kg or more, particularly soon after diagnosis—may lead to diabetes remission in some people. Oviva's approach focuses on sustainable lifestyle modification rather than restrictive dieting, emphasising gradual changes to eating patterns, physical activity, and behavioural habits.

Patients using Oviva receive support from qualified dietitians who specialise in diabetes and weight management. These professionals provide individualised advice based on each person's medical history, dietary preferences, cultural background, and personal goals. The service is particularly valuable for those who struggle with traditional face-to-face appointments due to work commitments, mobility issues, or geographical barriers. By offering flexible, remote access to specialist support, Oviva aims to improve engagement and long-term adherence to lifestyle interventions. Oviva is commissioned by some Integrated Care Boards (ICBs) within Integrated Care Systems (ICSs) in England, making it available to eligible patients at no cost in participating areas.

Key features of the Oviva platform include:

• One-to-one consultations with registered dietitians via video call or telephone

• A mobile app for tracking food intake, physical activity, and weight (not a medical monitoring device)

• Educational resources tailored to diabetes and obesity management

• Regular progress monitoring and goal adjustment

• Integration with NHS pathways for eligible patients in commissioned areas

How the Oviva Digital Platform Works for Weight Loss and Diabetes Care

The Oviva platform operates through a structured programme; duration varies by local ICS/ICB service specification and commonly ranges from 12 weeks to 12 months, depending on individual needs and commissioning arrangements. Upon enrolment, patients complete a comprehensive assessment covering medical history, current medications, dietary habits, activity levels, and personal goals. This information enables the assigned dietitian to develop a tailored care plan aligned with NICE guidance on obesity and type 2 diabetes management (NG28, NG246).

Patients download the Oviva app to their smartphone or tablet, which serves as the central hub for daily engagement. The app allows users to photograph meals, log food and drink intake, record physical activity, and track weight changes over time. This photo-based food diary is a distinctive feature that simplifies the often burdensome task of calorie counting, making it easier for patients to maintain consistent self-monitoring. The dietitian reviews these entries between consultations, providing asynchronous feedback and encouragement through the app's messaging function.

Regular consultations with the dietitian occur via video call or telephone, typically fortnightly initially, then reducing in frequency as patients progress. During these sessions, the dietitian reviews progress, addresses challenges, provides education on topics such as carbohydrate counting or portion control, and adjusts goals collaboratively. The approach uses evidence-based behaviour change methods, including motivational interviewing and cognitive behavioural therapy-informed strategies, helping patients identify and overcome barriers to change.

For individuals with type 2 diabetes, the platform supports medication optimisation by facilitating communication between the patient, dietitian, and prescribing clinician. As weight loss progresses and glycaemic control improves, diabetes medications may require adjustment or reduction. Only the patient's GP or prescribing clinician can change diabetes medications; the dietitian can alert the prescriber to progress and potential need for medication review, ensuring safe medication management.

Patients are advised to monitor blood glucose levels as directed by their healthcare team and report concerning readings promptly. Seek help if you experience:

• Repeated low blood glucose readings (below 4 mmol/L) or symptoms of hypoglycaemia (shaking, sweating, confusion)

• Persistent high blood glucose readings above your agreed target, especially if you feel unwell

• Symptoms of diabetic ketoacidosis (nausea, vomiting, abdominal pain, fruity breath odour, rapid breathing)—particularly if you take an SGLT2 inhibitor (e.g., dapagliflozin, empagliflozin, canagliflozin) and are unwell or making significant dietary changes

Contact your GP, diabetes team, or NHS 111 as appropriate. Follow NHS sick-day rules if you become unwell, and discuss your medication plan with your prescriber before starting any significant dietary restriction. For more information, see the NHS website pages on hypoglycaemia and hyperglycaemia in diabetes, and MHRA guidance on SGLT2 inhibitors and diabetic ketoacidosis risk.

Evidence and Clinical Outcomes: Does Oviva Improve Diabetes Control?

Clinical evidence supporting digital health interventions for diabetes and obesity has grown substantially in recent years. Oviva has been evaluated in studies demonstrating meaningful improvements in weight loss and glycaemic control. Published research examining outcomes in patients with type 2 diabetes using Oviva through NHS pathways has reported average weight loss and corresponding reductions in HbA1c. Service data suggest that engagement with the platform is associated with better outcomes—those who complete more consultations and log food intake regularly tend to achieve greater weight loss and HbA1c reduction. This highlights the importance of patient activation and the role of regular dietetic support in maintaining motivation.

Real-world NHS implementation data suggest that Oviva compares favourably to traditional face-to-face weight management services in terms of completion rates and weight loss outcomes. However, it is important to note that digital interventions may not suit everyone—some patients prefer in-person contact or lack confidence with technology. Digital health technologies are assessed using the NICE Evidence Standards Framework to ensure they meet appropriate quality and safety standards.

While the evidence is encouraging, diabetes remission is not guaranteed and depends on multiple factors, including the amount of weight lost, how long someone has had diabetes, and individual metabolic factors. Remission is defined as HbA1c below 48 mmol/mol (6.5%) sustained for at least three months after stopping diabetes medication (Diabetes UK definition). Substantial and sustained weight loss—often 15 kg or more, particularly soon after diagnosis—is more likely to support remission. The DiRECT trial demonstrated that intensive weight management programmes using very low-calorie diets can achieve remission in a significant proportion of participants. Sustained weight loss achieved through Oviva can contribute to improved metabolic health and may support remission in some individuals, particularly when combined with appropriate medical management. Patients should discuss realistic expectations and remission pathways with their healthcare team.

NHS Availability and Accessing Oviva Through Your GP

Oviva is commissioned by some Integrated Care Boards (ICBs) within Integrated Care Systems (ICSs) across England, making it available to eligible patients at no cost in participating areas. Availability varies by region, so not all areas currently offer Oviva as part of their diabetes or weight management pathways. Patients interested in accessing the service should first consult their GP or practice nurse to determine local availability and eligibility criteria.

Typical eligibility criteria include:

• Diagnosis of type 2 diabetes or prediabetes (HbA1c 42–47 mmol/mol)

• Body mass index (BMI) ≥30 kg/m², or ≥27.5 kg/m² for individuals from South Asian, Chinese, Black African, Black Caribbean, or other minority ethnic groups at higher risk (NICE PH46)

• Willingness to engage with digital technology and attend remote consultations

• Usually aged 18 years or over

• Not pregnant or breastfeeding

• No contraindications such as active eating disorders requiring specialist input or significant unmanaged mental health concerns

Final eligibility criteria are set locally and may vary. Referral processes differ by locality. In some areas, GPs can refer directly through local referral hubs or electronic systems; in others, patients may self-refer via online portals after obtaining GP approval. Check your local ICS/ICB service finder or ask your GP practice for details. Once referred, patients typically receive contact from Oviva within a few days to arrange an initial assessment and begin the programme.

For patients in areas where Oviva is not commissioned, alternative NHS services may be available, including:

• NHS Diabetes Prevention Programme (NDPP) for people with prediabetes

• NHS Digital Weight Management Programme (12-week digital programme for eligible adults with obesity and a related health condition)

• NHS Type 2 Diabetes Path to Remission Programme (low-calorie diet programme for eligible patients aiming for remission)

• Tier 2 weight management programmes delivered locally

• Referral to specialist weight management services (Tier 3) for individuals with complex needs

Private access to Oviva is also possible for those willing to pay, though costs can be substantial. Patients should discuss all available options with their GP to identify the most appropriate pathway for their circumstances.

Comparing Oviva to Traditional Diabetes and Weight Management Services

Traditional NHS weight management and diabetes education services typically involve group-based sessions or individual face-to-face appointments with dietitians, diabetes specialist nurses, or health trainers. These services have a strong evidence base and remain the cornerstone of lifestyle intervention for many patients. NICE guidance (NG28, NG246) recommends multicomponent interventions incorporating dietary advice, physical activity support, and behavioural change techniques, regardless of delivery mode. Structured diabetes education programmes meeting NICE quality standards are also recommended to support self-management.

Oviva offers several advantages over traditional models. The digital-first approach provides greater flexibility, allowing patients to engage with support around work and family commitments without travel time. The ongoing nature of app-based self-tracking enables more frequent touchpoints between formal consultations, potentially enhancing accountability and motivation. For patients in rural areas or those with mobility limitations, remote access removes significant barriers to participation.

However, digital platforms are not universally suitable. Older adults or those with limited digital literacy may struggle with app-based interfaces, though Oviva does provide telephone support as an alternative to video consultations. Patients with language barriers, visual or hearing impairments, or limited internet connectivity may require additional support; interpreter services and accessibility adjustments should be discussed with the service provider. Some patients value the peer support and social interaction inherent in group-based programmes, which digital platforms cannot fully replicate. The effectiveness of any intervention depends largely on programme design, patient engagement, and the skill of the supporting clinicians.

From a health system perspective, digital platforms like Oviva offer potential cost-effectiveness and scalability. They can reach larger numbers of patients without proportional increases in physical infrastructure. However, they require investment in technology, data security, and training for healthcare professionals. The choice between digital and traditional services should be individualised through shared decision-making, considering patient preferences, clinical needs, digital inclusion, and local service availability. Patients uncertain about which approach suits them best should discuss options with their GP or diabetes care team.

Frequently Asked Questions